Portfolio Alerts Watch List Cart

Healthcare

Refine Search


Product Compare (0)
J
Jagsonpal Pharmaceuticals Ltd
Score 68/100• Decent
Jagsonpal Pharmaceuticals Ltd shows potential but faces significant challenges in profitability and valuation metrics. Caution is advised for investors.
Company’s Health94/100
Valuation 20/100 · PB 6.1975
Technical Avoid
1M -12.389% 6M 1.586% 1Y 22.672%
Confidence100%
Low leverage (D/E)No promoter pledge
#91
View details ➜
J
J B Chemicals and Pharmaceuticals Ltd
Score 68/100• Decent
J B Chemicals and Pharmaceuticals Ltd shows decent potential with a stable growth outlook, but investors should be cautious of execution risks and valuation metrics.
Company’s Health95/100
Valuation 20/100 · PB 7.6056
Technical Avoid
1M -2.377% 6M 4.775% 1Y -11.567%
Confidence100%
Low leverage (D/E)No promoter pledge
#92
View details ➜
I
IPCA Laboratories Ltd
Score 68/100• Decent
IPCA Laboratories Ltd shows potential for growth, but investors should be cautious due to profitability inconsistencies and valuation concerns.
Company’s Health80/100
Valuation 40/100 · PB 3.9237
Technical Avoid
1M -0.978% 6M -5.168% 1Y -23.834%
Confidence100%
Low leverage (D/E)No promoter pledge
Weak ROE
#93
View details ➜
I
Indoco Remedies Ltd
Score 68/100• Decent
Indoco Remedies Ltd shows potential for growth but faces challenges in profitability and valuation metrics.
Company’s Health56/100
Valuation 60/100 · PB 2.5887
Technical Avoid
1M -1.09% 6M 22.521% 1Y -14.879%
Confidence100%
No promoter pledgeReasonable PB valuation
Weak ROEThin margins
#94
View details ➜
H
Hindustan Bio Sciences Ltd
Score 68/100• Decent
Hindustan Bio Sciences Ltd shows potential but faces significant challenges in growth and profitability metrics. Caution is advised for investors.
Company’s Health33/100
Valuation 20/100 · PB 9.6699
Technical Avoid
1M 0.386% 6M -4.176% 1Y -11.655%
Confidence100%
No promoter pledgeHealthy profit margins
Weak ROEHigh debt/equity
#95
View details ➜
G
Gufic Biosciences Ltd
Score 68/100• Decent
Gufic Biosciences Ltd shows potential for growth in a promising sector, but faces challenges in profitability and valuation metrics. Investors should proceed with caution.
Company’s Health90/100
Valuation 20/100 · PB 6.0646
Technical Avoid
1M -1.07% 6M 6.77% 1Y -10.841%
Confidence100%
No promoter pledge
#96
View details ➜
F
Fortis Healthcare Ltd
Score 68/100• Decent
Fortis Healthcare Ltd shows potential in a growing sector but faces challenges in execution and competition. Caution is advised.
Company’s Health67/100
Valuation 20/100 · PB 8.9547
Technical Momentum
1M 11.709% 6M 62.51% 1Y 75.504%
Confidence100%
Low leverage (D/E)No promoter pledge
Weak ROE
#97
View details ➜
D
Dr Lalchandani Labs Ltd
Score 68/100• Decent
Dr Lalchandani Labs Ltd shows potential in a growing sector, but faces challenges in growth consistency and valuation metrics. Caution is advised.
Company’s Health50/100
Valuation 100/100 · PB 0.989
Technical Avoid
1M -7.143% 6M 81.371% 1Y 16.771%
Confidence100%
Low leverage (D/E)No promoter pledge
Weak ROE
#98
View details ➜
D
Dr Agarwal's Eye Hospital Ltd
Score 68/100• Decent
Dr Agarwal's Eye Hospital Ltd shows potential for growth, but faces challenges in profitability and valuation metrics compared to peers.
Company’s Health68/100
Valuation 20/100 · PB 11.3938
Technical Avoid
1M 6.941% 6M 23.03% 1Y -3.393%
Confidence100%
Healthy profit marginsDecent revenue growth
High debt/equityPromoter pledge present
#99
View details ➜
D
DocMode Health Technologies Ltd
Score 68/100• Risky
DocMode Health Technologies Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
Company’s Health44/100
Valuation 40/100 · PB 4.0838
Technical Momentum
1M 153.452% 6M 119.192% 1Y 16.479%
Confidence100%
Weak ROEPromoter pledge present
#100
View details ➜
C
Concord Biotech Ltd
Score 68/100• Decent
Concord Biotech Ltd shows potential for growth but faces challenges in valuation and execution risks.
Company’s Health94/100
Valuation 20/100 · PB 8.7001
Technical Avoid
1M -7.8% 6M -13.017% 1Y -22.077%
Confidence100%
Low leverage (D/E)No promoter pledge
#101
View details ➜
B
Bharat Parenterals Ltd
Score 68/100• Decent
Bharat Parenterals Ltd shows potential for growth, but faces challenges in profitability and market competition.
Company’s Health64/100
Valuation 60/100 · PB 2.5077
Technical Avoid
1M -10.192% 6M 25.477% 1Y -16.288%
Confidence100%
No promoter pledgeDecent revenue growth
Weak ROEThin margins
#102
View details ➜
A
Asarfi Hospital Ltd
Score 68/100• Decent
Asarfi Hospital Ltd shows potential in a growing sector but faces challenges in profitability and valuation. Caution is advised.
Company’s Health89/100
Valuation 40/100 · PB 3.2848
Technical Avoid
1M -7.531% 6M 59.021% 1Y 118.065%
Confidence100%
No promoter pledgeDecent revenue growth
#103
View details ➜
A
Aspira Pathlab & Diagnostics Ltd
Score 68/100• Decent
Aspira Pathlab & Diagnostics Ltd shows potential for growth but faces challenges in profitability and valuation metrics. Caution is advised.
Company’s Health77/100
Valuation 40/100 · PB 4.9933
Technical Avoid
1M 3.969% 6M 8.516% 1Y 38%
Confidence100%
Low leverage (D/E)No promoter pledge
#104
View details ➜
A
Aristo Bio-Tech and Lifescience Ltd
Score 68/100• Decent
The company operates in a promising sector but faces challenges in growth consistency and profitability metrics.
Company’s Health72/100
Valuation 60/100 · PB 2.462
Technical Avoid
1M -5.294% 6M -5.594% 1Y 13.445%
Confidence100%
No promoter pledgeDecent revenue growth
Weak ROEThin margins
#105
View details ➜
Showing 91 to 105 of 301 (21 Pages)